Curis Inc (NASDAQ:CRIS)

2.30
Delayed Data
As of Jun 20
 +0.02 / +0.88%
Today’s Change
2.07
Today|||52-Week Range
11.35
-34.29%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$100.2M

Company Description

Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Contact Information

Curis, Inc.
4 Maguire Road
Lexington Massachusetts 02421
P:(617) 503-6500
Investor Relations:

Employees

Shareholders

Other institutional28.60%
Mutual fund holders12.48%
Individual stakeholders0.56%

Top Executives

Ali FattaeyPresident, Chief Executive Officer & Director
James E. DentzerCOO, CFO, CAO, Secretary & Treasurer
Robert E. MartellHead-Research & Development
David TuckChief Medical Officer & Senior Vice President